Tongue tingling; Tachycardia/heart racing; HR was around 105-110 and bounding for about 1 minute; Nausea; This is a spontaneous report from a contactable other HCP (healthcare professional) who responded to an HCP letter that was sent. A 33-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; solution for injection; Lot #: EK9231) intramuscularly on 09Jan2021 at 14:00 (at the age of 33-years-old) as a single dose in the right arm for COVID-19 immunization. Medical history was reported as none. Concomitant medications included drospirenone/ethinylestradiol (OCELLA) taken as an oral contraceptive (OCP) from 04Jan2021 to an unspecified date and cetirizine hydrocholoride (ZYRTEC ALLERGY) taken as a premedication for 3 days prior to 2nd dose. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; solution for injection; Lot #: EK5730) intramuscularly on 19Dec2020 at 13:00 (at the age of 33-years-old) in the left arm and experienced tingling of left arm, paresthesia of tongue, heart racing, feeling of lump in my throat and anaphylactic reaction. The patient previously received Bactrim on an unspecified date and experienced allergy. Prior vaccinations within 4 weeks were reported as not applicable and it was reported that the patient had not received any other vaccines around the time of the COVID-19 vaccine. The patient experienced "tongue tingling" on 09Jan2021, "tachycardia/heart racing", "HR (heart rate) was around 105-110) and bounding for about 1 minute" and "nausea" in Jan2021.  It was reported that "I was re-dosed with the vaccine dose on 19Jan2021 (as reported) at 2pm. I took Zyrtec (Cetirizine) for 3 days prior. About 5 minutes after the vaccine was administered, I had tongue tingling that lasted approximately 5 minutes, I took 25mg of Benadryl and the tingling did not reoccur." It was also reported that "nausea occurred immediately after vaccine administration". The patient stated that her "heart was racing approximately 6-7 minutes after and lasted about 1 minute". It was reported that none of the events were considered serious due to being life-threatening or due to persistent or significant disability/incapacity. The adverse events did not require a visit to the emergency room or physician office and did not require medical intervention. The patient was not hospitalized due to the events. The patient was not admitted to an intensive care unit. It was reported that the patient did not have any bilateral wheeze/bronchospasm, stridor, upper airway swelling, respiratory distress, tachypnea, increased use of accessory respiratory muscles, recession, cyanosis, grunting, dry cough, hoarse voice, difficulty breathing, sensation of throat closure, sneezing, rhinorrhea, measured hypotension, shock, capillary refill time greater than 3 seconds, reduced central pulse volume, decreased level of consciousness, loss of consciousness, generalized urticaria, generalized erythema, angioedema, generalized pruritus with skin or without skin rash, localized injection site urticaria, red and itchy eyes, diarrhea, abdominal pain or vomiting. Relevant tests were reported as not applicable. It was also reported that a culture was not performed. The clinical outcomes of the events "tongue tingling", "tachycardia/heart racing", "HR (heart rate) was around 105-110) and bounding for about 1 minute" and "nausea" were all recovered/resolved on unspecified dates.   The reporter considered that there was a reasonable possibility that the events were related to BNT162B2.